| Oct 16 |
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
|
| Oct 16 |
Strength Seen in Cencora (COR): Can Its 3.7% Jump Turn into More Strength?
|
| Oct 15 |
Viatris Settles Lawsuit, Avoids Antitrust Charges, and Advances Effexor Study
|
| Oct 14 |
Viatris Inc. (VTRS): David Einhorn’s Top Stock Pick
|
| Oct 12 |
Viatris Inc. (VTRS): A Strategic Shift in Healthcare Investments
|
| Oct 10 |
Viatris 2023 Sustainability Report: Reducing Packaging Material
|
| Oct 9 |
Viatris Inc (VTRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations
|
| Oct 9 |
Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)
|
| Oct 8 |
Is Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20?
|
| Oct 8 |
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row
|
